Southeast Asset Advisors Boosts AbbVie Stake by 63%

Hedge fund increases holdings in pharmaceutical giant to $5.8 million

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

Southeast Asset Advisors LLC, a financial advisory firm, has increased its stake in AbbVie Inc. (NYSE: ABBV) by 63% during the third quarter. The firm now owns 25,311 shares of the pharmaceutical company's stock, valued at $5.86 million.

Why it matters

AbbVie is a major player in the pharmaceutical industry, known for its blockbuster drugs like Humira. The increase in Southeast Asset Advisors' stake suggests the firm sees continued growth potential in AbbVie's business and stock performance.

The details

According to the report, Southeast Asset Advisors added 9,782 shares of AbbVie to its portfolio during the third quarter. This brings the firm's total holdings in AbbVie to 25,311 shares, making it the 23rd largest position in its investment portfolio.

  • Southeast Asset Advisors increased its AbbVie stake during the third quarter of the year.
  • AbbVie's stock price ranged from a 12-month low of $164.39 to a high of $244.81 during the period.

The players

Southeast Asset Advisors LLC

A financial advisory firm that manages investments for its clients.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The increase in Southeast Asset Advisors' stake in AbbVie suggests the firm sees continued growth potential in the pharmaceutical company's business and stock performance, underscoring the company's position as a major player in the industry.